First experience of using ivermectin and brimonidine tartrate in patients with rosacea: case studies

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Lvov A.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Hlystova E.A.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Kochetkov M.A.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

First experience of using ivermectin and brimonidine tartrate in patients with rosacea: case studies

Authors:

Potekaev N.N., Lvov A.N., Hlystova E.A., Kochetkov M.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2017;16(2): 117‑125

DOI: 10.17116/klinderma2017162117-125

Downloaded: 545

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Potekaev NN, Lvov AN, Hlystova EA, Kochetkov MA. First experience of using ivermectin and brimonidine tartrate in patients with rosacea: case studies. Russian Journal of Clinical Dermatology and Venereology. 2017;16(2):117‑125. (In Russ.)
https://doi.org/10.17116/klinderma2017162117-125

Close metadata

We present the relevant data on etiology, pathogenesis, and modern rosacea treatment. The clinical cases and the first data obtained during follow-up of patients receiving topical therapy with 1% ivermectin cream and 0.5% brimonidine tartrate gel are reported.

Keywords:

rosacea therapy

papulopustular rosacea

erythematotelangiectatic rosacea

steroid-induced rosacea

1% ivermectin cream

05% brimonidine tartrate gel

first experience

Authors:

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Lvov A.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Hlystova E.A.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Kochetkov M.A.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

List of references:

Potekaev NN. Rozatsea. Etiologiya, klinika, terapiya. M—SPb.: Izdatel'stvo «Binom», «Nevskii dialekt». 2000. (In Russ.).
Tan J, Schöfer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M; RISE study group. Prevalence of rosacea in the general population of Germany and Russia — The RISE study. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):428-434.
Potekaev NN, Khamaganova IV, Novozhilova OL, Lebedeva GA. Epidemiologiya rozatsea. Klinicheskaya dermatologiya i venerologiya. 2016;15(1):4-7. (In Russ.).
Chosidow O, Cribier B. Epidemiology of rosacea. Dermatol Venereol. 2011;138(Suppl. 3):179-183.
Dorozhenok IYu, Belousova TA, Terent'eva MA. Nozogennye reaktsii u bol'nykh dermatozami fatsial'noi lokalizatsii. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2006;1:41-45. (In Russ.).
Yu Ri Woo, Ji Hong Lim, Dae Ho Cho, Hyun Jeong Park. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016 Sep 15;17(9).
Olisova OYu, Kochergin NG, Smirnova EA. Sovremennaya naruzhnaya terapiya srednetyazhelykh form rozatsea. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2016;6:328-333. (In Russ.).
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69:6:Suppl. 1:15-26.
Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013;69:6:Suppl. 1:S57-S65.
Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs. Dermatol. 2012;11:6:725-730.
Gomaa AHA, Yaar M, Eyada MM, et al. Lymphangiogenesis and angiogenesis in nonphymatous rosacea. J Cutan Pathol. 2007;34(10):748-753.
Gupta MA, Gupta AK, Chen SJ, et al. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey — Outpatient Department data collected by the U. S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176-1181.
Zouboulis CC, Katsambas AD, Kligman AM. Pathogenesis and Treatment of Acne and Rosacea. Berlin: Springer. 2014.
Olisova OYu, Dodina MI, Kushlinskii NE. Rol' faktora rosta sosudistogo endoteliya v patogeneze rozatsea i ego medikamentoznaya korrektsiya. Klinicheskaya dermatologiya i venerologiya. 2012;1:49-55. (In Russ.).
Palatsi R, Kelhälä H-L, Hägg P. New insights in the pathogenesis and treatment of rosacea. Duodecim. 2012;128:2327-2335.
Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol Society for Investigative Dermatology Inc. 2011;131(3):688-697.
Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield F, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014 Jan;93(1):18-28.
Del Rosso JQ, Schlessinger J, Werschler P. Comparison of Anti-inflammatory Dose Doxycycline versus Doxycycline 100 mg in the Treatment of Rosacea. J Drugs Dermatol. 2008;7(6):573-576.
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):15-26.
Stein L, Kircik L, Fowler J, Tan J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of Drugs in Dermatology. 2014;13(3):316-323.
Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J. Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0,75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015 Apr;172(4):1103-1110. doi:10.1111/bjd.13408. Epub 2015 Feb 11
Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J, Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. Journal of Drugs in Dermatology. 2014;13(11):1380-1386.
Fowler JJr, Jackson M, Moore A, Jarratt M, Jones T, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of Drugs in Dermatology. 2013;12(6):650-656.
Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M., on behalf of the Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology. 2012;66:633-641.
Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015;29:2405-2410.
Moore A, Kempers S, Murakawa G, Weiss J, Tauscher, Swinyer L, Liu H, Leoni M. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. Journal of Drugs in Dermatology. 2014;13(1):56-61.
Plewig G, Kligmn AM. Acne and Rosacea. Springer Science & Business Media. 2012.

Close metadata